Raymond James & Associates Buys New Stake in Halozyme Therapeutics, Inc. (HALO)

Raymond James & Associates bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,151 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in HALO. BlackRock Inc. grew its position in Halozyme Therapeutics by 5.7% during the second quarter. BlackRock Inc. now owns 12,242,431 shares of the biopharmaceutical company’s stock valued at $206,530,000 after buying an additional 659,763 shares during the period. Dimensional Fund Advisors LP bought a new stake in Halozyme Therapeutics during the first quarter valued at approximately $7,167,000. Wells Fargo & Company MN grew its position in Halozyme Therapeutics by 60.3% during the second quarter. Wells Fargo & Company MN now owns 535,697 shares of the biopharmaceutical company’s stock valued at $9,038,000 after buying an additional 201,507 shares during the period. UBS Group AG grew its position in Halozyme Therapeutics by 121.8% during the first quarter. UBS Group AG now owns 183,556 shares of the biopharmaceutical company’s stock valued at $3,595,000 after buying an additional 100,813 shares during the period. Finally, First Quadrant L P CA grew its position in Halozyme Therapeutics by 309.3% during the second quarter. First Quadrant L P CA now owns 100,933 shares of the biopharmaceutical company’s stock valued at $1,703,000 after buying an additional 76,271 shares during the period. Institutional investors own 84.68% of the company’s stock.

In other news, major shareholder Randal J. Kirk sold 490,072 shares of the business’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $17.30, for a total value of $8,478,245.60. Following the transaction, the insider now owns 3,562,388 shares of the company’s stock, valued at $61,629,312.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Randal J. Kirk sold 146,718 shares of the business’s stock in a transaction on Wednesday, August 8th. The stock was sold at an average price of $17.52, for a total transaction of $2,570,499.36. Following the completion of the transaction, the insider now directly owns 3,562,388 shares in the company, valued at approximately $62,413,037.76. The disclosure for this sale can be found here. Insiders have sold 3,513,468 shares of company stock worth $61,759,078 in the last ninety days. Insiders own 16.80% of the company’s stock.

Shares of NASDAQ:HALO opened at $16.03 on Friday. The company has a current ratio of 3.49, a quick ratio of 3.43 and a debt-to-equity ratio of 0.31. Halozyme Therapeutics, Inc. has a 1-year low of $14.33 and a 1-year high of $21.48. The company has a market cap of $2.24 billion, a price-to-earnings ratio of 35.62 and a beta of 1.87.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.06. Halozyme Therapeutics had a net margin of 23.88% and a return on equity of 38.10%. The business had revenue of $35.20 million for the quarter, compared to the consensus estimate of $31.49 million. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post -0.81 EPS for the current fiscal year.

HALO has been the subject of several recent research reports. Cantor Fitzgerald set a $27.00 target price on shares of Halozyme Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 2nd. ValuEngine upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, October 3rd. BidaskClub upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, October 3rd. BMO Capital Markets boosted their target price on shares of Halozyme Therapeutics from $19.00 to $21.00 and gave the company a “market perform” rating in a research report on Wednesday, August 8th. Finally, Piper Jaffray Companies started coverage on shares of Halozyme Therapeutics in a report on Thursday, October 18th. They set a “hold” rating and a $17.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. Halozyme Therapeutics presently has a consensus rating of “Hold” and an average target price of $20.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Featured Article: Analyzing a company’s cash flow statement

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply